There is something fitting about a magazine called Cognitio arriving at this particular moment. The word means knowledge, and knowledge, as this edition makes clear, is precisely what Australia's life sciences sector is being asked to generate, apply, and rethink at pace.

Issue 60 of Cognitio lands in the weeks before the 2026 ARCS Annual Conference, and it reads like a field report from the front lines of a sector navigating genuine complexity. The theme, Life Sciences Unlocked: AI, Access and Evidence Across a Changing Sector, was chosen to reflect what contributors across this edition are actually experiencing in their day-to-day work. Read through these pages and that choice feels well-calibrated.

The conversation that runs most persistently through this issue is about artificial intelligence. Not AI as aspiration, but AI as a practical challenge being worked through in real organisations. Jeremy Collins from Nucleus Network writes with unusual candour about the lessons his team learned deploying large language models in clinical trial settings, including where the technology plateaus and why human oversight cannot be retrofitted after the fact. Mark Thomas from Mexec maps the broader workforce picture, drawing on recent government and industry data to argue that AI fluency is fast becoming a baseline professional competency rather than a specialist skill. Both articles reward careful reading before the conference sessions on digital transformation begin.

Access is the second thread that weaves through the issue. Rima Darwiche describes how Central Pharmacy Logistics is addressing one of the most persistent structural gaps in decentralised trials, the inability to prepare and deliver infusion therapies beyond hospital settings. Goce Bodeski reflects on the surprising parallels between device and pharmaceutical market access pathways, two disciplines that more professionals are being asked to navigate simultaneously. Steven Haken provides a clear-eyed account of Europe's Joint Clinical Assessments after their first year in operation, an analysis with direct implications for Australian sponsors thinking about global evidence strategy.

The evidence theme is equally prominent. Geoff Bloom and his colleagues at Mills Oakley walk through the FDA's credibility assessment framework for AI-generated regulatory submissions, a framework that matters here regardless of jurisdiction. Andrew Rankine and Katrina Crooks from Spruson and Ferguson cover skinny labelling in the Australian context, one of those technically precise topics that has significant commercial consequences and rarely gets the accessible treatment it receives here.

ARCS itself features throughout. Nav Lee writes about the membership growth that has reshaped the organisation's national footprint, reaching nearly 2,800 members across 675 organisations. Anna Megalakakis provides an education update that captures the breadth of what has been delivered in the first half of 2026 across training, webinars, and the developing College structure. Jack Lambshead reports on the ARCS and DIA Cell and Gene Therapy Summit, distilling a day of concentrated expert discussion into the strategic signals that matter most for the Australian ecosystem.

Carl Bufe, Nina Mapson Bone, Clara Choi, and Leon Rozen round out an edition that covers pharmacovigilance, board governance, sustainability, mentorship, and intellectual property with the same practical orientation that defines the journal at its best.

What Issue 60 makes clear, read as a whole, is that the professionals gathering in Sydney for the 2026 ARCS Annual Conference are not arriving with abstract questions. They are arriving with the real ones: how to apply AI responsibly, how to get innovative therapies to patients faster, and how to build the evidence that regulators and payers will actually trust.

This edition is the conversation starter. The conference is where it continues.

Cognitio Issue 60 is available exclusively to ARCS members via the Cognitio platform at cognitio.arcs.com.au